Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Complete title: SC-2026 Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)

Research Study Number SC-2026
 
Principal Investigator Todd Cooper
 
Phase I

Research Study Description

This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML).

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number SC-2026
 
Contact Sini Sreenivas
 
Telephone 206/884-1480
 
E-mail
 

Keywords: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Pediatric Cancers, Miscellaneous; Leukemia, Myeloid

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials